Thyroglossal Duct Cyst & Thyroglossal Fistula

1. Embryological Basis

2. Thyroglossal Duct Cyst (TDC)

Definition

Location

• Can occur anywhere along the migratory path of the thyroid — from the base of the tongue to just above the isthmus
• ~80% are found at or just below the hyoid bone (juxtahyoid position)
• ~20% are suprahyoid; rarely, a TDC forms at the base of the tongue (lingual thyroglossal cyst) or within the thyroid itself (intrathyroidal)

Clinical Features

Complications

1. Infection — most common; often triggered by upper respiratory tract infections via oral bacteria ascending through a patent duct. Results in abscess formation
2. Fistula formation — infected cysts may spontaneously rupture through the skin, creating a thyroglossal fistula (see below)
3. Malignant transformation — exceedingly rare (~1% of cases); usually papillary thyroid carcinoma (most common), followed by squamous cell carcinoma. The identification of malignancy within a TDC is associated with a 6.6% risk of microcarcinoma in the normal-appearing thyroid gland. Suspect malignancy if the cyst grows rapidly or ultrasound shows a complex anechoic pattern or calcification
4. Ectopic thyroid — rarely, the TDC may represent the patient's only thyroid tissue (especially if the thyroid fails to descend — lingual thyroid). This occurs when caudal migration of the thyroid is arrested

Histopathology (Robbins Pathology)

• Wall lined by stratified squamous epithelium near the tongue base, or pseudostratified ciliated columnar (respiratory) epithelium in lower positions
• Transitional epithelial differentiation patterns also occur
• Fibrous cyst wall often includes lymphoid aggregates and thyroid follicular remnants (heterotopic thyroid tissue present in ~20% of cases)

Diagnosis

1. Clinical — characteristic midline neck mass moving with tongue protrusion is usually sufficient
2. Ultrasound — first-line imaging; confirms cystic nature, confirms presence of a normal orthotopic thyroid gland in the neck (critical — must rule out that the TDC is not the only thyroid tissue before surgery). Also identifies infection, septa, solid components
3. CT/MRI — for large or atypical lesions; delineates extent and relationship to surrounding structures
4. Thyroid scintigraphy (radionuclide scan) — used selectively when US is inconclusive about whether normal thyroid tissue is present
5. FNAC — can rule out malignancy in suspicious lesions

Important: Routine thyroid function tests and nuclear imaging are not required preoperatively in all cases. However, if a normal thyroid cannot be palpated or confirmed on US, further investigation is mandatory before surgery.

3. Thyroglossal Fistula

Definition & Pathogenesis

• It is almost always a secondary event, arising after:
  • Spontaneous rupture of an infected thyroglossal duct cyst through the skin
  • Incision and drainage of an abscess formed within a TDC (inadequate/incomplete primary surgery)
  • Rarely, it may be present at birth as a primary congenital anomaly (Langman's Medical Embryology)
• Unlike branchial cleft fistulas (which are true fistulas with two openings from the outset), thyroglossal fistulas are typically sinuses with only one external opening — the term "fistula" is used loosely since the internal opening at the foramen cecum may not always be patent

Anatomy of the Tract

• The external opening lies in the median plane of the anterior neck, anterior to the laryngeal cartilages (typically between the hyoid bone and the thyroid notch)
• The tract runs superiorly, passing through or closely related to the body of the hyoid bone, ultimately directed toward the foramen cecum at the tongue base
• The tract is lined by pseudostratified ciliated columnar epithelium (similar to the cyst) with surrounding fibrous tissue and lymphoid infiltrate

Clinical Features

• Intermittent discharge of mucoid or mucopurulent material from a midline neck opening
• The opening may appear as a small dimple or pore with surrounding skin changes (induration, granulation tissue, erythema)
• History of a previously swollen midline neck mass that spontaneously drained or was incised
• Periodic flare-ups with discharge, especially after URTI
• The tract moves with swallowing/tongue protrusion (like the cyst)

Diagnosis

• Clinical — history + midline location
• Fistulogram/sinogram — injection of contrast to delineate the tract
• Ultrasound — may trace the tubular tract
• CT/MRI — for complex or recurrent cases

4. Surgical Treatment: The Sistrunk Procedure

The Procedure Includes:

1. Complete excision of the cyst (or fistulous tract)
2. Resection of the central portion (body) of the hyoid bone — this is essential because the tract is intimately associated with or passes through the hyoid, and residual hyoid periosteum leads to recurrence
3. Excision of the tract from below the hyoid continuing superiorly as a core of muscle (genioglossus) up to the foramen cecum at the base of the tongue — ensuring no duct epithelium is left behind
4. Ligation at the foramen cecum — a pharyngotomy may be required; a modification of the procedure omits formal pharyngotomy

Outcomes

• More than 2 episodes of infection prior to surgery
• Age under 2 years at time of surgery
• Inadequate initial operation (especially failure to include hyoid body)
• Prior incision and drainage

Surgical Illustration

Management of Infected TDC/Fistula

1. Acute phase: IV/oral antibiotics; if fluctuant → incision and drainage (not definitive excision)
2. Definitive surgery: Defer until full resolution of acute inflammation (usually 4–6 weeks). Operating through inflamed tissue dramatically increases recurrence risk and wound complications

5. Important Differentials (Midline Neck Masses)

6. Malignancy in TDC

• Incidence: ~1% of all TDCs
• Most common histotype: papillary thyroid carcinoma (>90%); rarely squamous cell carcinoma, Hurthle cell carcinoma
• Suspect if: solid or mixed echogenicity on US, rapid growth, hard consistency, associated cervical lymphadenopathy, calcifications on imaging
• Management: Sistrunk procedure is sufficient for most intrinsic TDC carcinomas. Thyroidectomy is not automatically required but the thyroid should be closely evaluated and monitored lifelong given the 6.6% risk of concurrent microcarcinoma in the thyroid gland (Cummings Otolaryngology, 2024)

Key Summary Points

• Thyroglossal duct cyst carcinomas — systematic review (PMID 40347268) — confirms Sistrunk as definitive treatment; thyroidectomy not mandated by TDC carcinoma alone
• Diagnostic utility of thyroid scan and ultrasound in TDC management (PMID 40757114) — supports routine ultrasound; nuclear scan reserved for equivocal cases

Ménière Disease — A Detailed Review

1. Historical Background

2. Definition

3. Epidemiology

4. Pathogenesis & Pathophysiology

4a. Anatomy of Endolymph

• Endolymph — high K⁺, low Na⁺; produced by the stria vascularis (cochlea) and dark cells (vestibular labyrinth)
• Perilymph — high Na⁺, low K⁺; resembles extracellular fluid

4b. Endolymphatic Hydrops

• Surgical disruption of the endolymphatic sac in animals consistently produces hydrops
• Perisaccular fibrosis and decreased endolymphatic duct size found in affected temporal bones
• CT and MRI show hypoplasia of the endolymphatic sac/duct and reduced vestibular aqueduct visualization in MD patients
• MRI after gadolinium shows enhancement of the endolymphatic sac and perilymphatic space
• These anatomic variations develop by age 3 and may represent a predisposing factor

4c. How Hydrops Causes Symptoms

1. Membrane rupture theory — Increased endolymphatic pressure causes rupture of the membranous labyrinth (Reissner membrane), allowing K⁺-rich endolymph to flood into the perilymph → depolarization block of cochlear and vestibular neurons → sudden deafness and vertigo. As the rupture heals and ionic gradients restore, symptoms resolve
2. Pressure/distortion theory — Mechanical distortion of the sensory epithelium and hair cells by pressure fluctuations alters their firing pattern

4d. Etiology of Idiopathic Endolymphatic Hydrops

• Impaired endolymph absorption (dysfunctional endolymphatic sac)
• Autoimmune mechanisms — association with HLA-B8/DR3 and Cw7; familial cases linked to autoimmune disease
• Viral/infective — prior herpes virus infection postulated in some cases
• Migraine — strong association, especially in familial MD
• Gluten sensitivity — recently implicated
• Anatomic predisposition — small vestibular aqueduct
• Genetic factors — autosomal dominant, recessive, and mitochondrial inheritance described; no specific gene identified yet

When a known disease causing hydrops is identified (syphilis, trauma, autoimmune disease, labyrinthitis, etc.), the diagnosis is secondary endolymphatic hydrops — not Ménière disease, which is strictly idiopathic.

5. Clinical Features

5a. The Classic Tetrad (AAO-HNS Criteria)

5b. Symptom Pattern and Natural History

• Hallmark: Dramatic variability and unpredictability
• Attacks may cluster and then remit for months to years
• Between attacks, patients may be entirely asymptomatic, or describe chronic disequilibrium/lightheadedness
• ~60% achieve spontaneous remission over time
• ~85% unilateral at onset; bilateral disease develops in ~20–30%, often within 36 months of second-ear involvement; up to 50% over 20 years
• Hearing loss: fluctuates early; tends to progressively stabilize at a moderate flat loss over years

5c. Important Variants

• Reversed Ménière: tinnitus, hearing loss, and aural fullness progressively worsen → then suddenly resolve when vertigo occurs
• The vertiginous episode paradoxically relieves the auditory symptoms
• Temporal bone studies showed hydrops and membrane ruptures isolated to basal cochlear turns and saccule

• Fluctuating SNHL and tinnitus without episodic vertigo
• Considered a forme fruste

• Episodic vertigo + aural fullness without documented hearing loss

• Sudden, violent fall without warning, loss of consciousness, or associated vertigo
• Thought to represent acute utriculosaccular dysfunction → erroneous vertical gravity reference → inappropriate vestibulospinal reflex → sudden fall
• Patients describe being "pushed" or "thrown" to the ground
• Occur in 2–6% of MD patients; tend to cluster then spontaneously remit
• Injury is common due to the abrupt, unprotected fall

• Profound SNHL occurs in one ear (from previous infection, etc.)
• Years later, symptoms of endolymphatic hydrops develop either in the same ear (ipsilateral) or opposite ear (contralateral)

6. Diagnostic Criteria (AAO-HNS 1995)

Definitive vertigo episode = spontaneous rotational vertigo lasting ≥20 min, not attributable to another cause

7. Investigations

7a. Audiometry (Pure Tone Audiogram)

• Low-frequency SNHL (250–1000 Hz) — characteristic early finding
• Carhart notch at 2000 Hz occasionally
• Fluctuating pattern — repeat audiograms over time are essential
• No tone decay (distinguishes from retrocochlear pathology)
• Recruitment present (loudness recruitment on SISI test)

7b. Electrocochleography (ECoChG)

• Measures cochlear electrical potentials in response to sound
• Elevated summating potential/action potential (SP/AP) ratio (>0.4) suggests endolymphatic hydrops
• Useful for confirming cochlear hydrops but not universally abnormal

7c. Electronystagmography (ENG) / Videonystagmography (VNG)

• Between attacks: may show reduced caloric response on the affected side (reflects vestibular hypofunction)
• During attacks: spontaneous horizontal nystagmus — direction changes over the course of the attack (not useful for lateralization)
• Head thrust test (video head impulse test): usually normal between attacks

7d. Glycerol Test (Dehydration Test)

• Oral glycerol 1.2 mL/kg + equal volume saline (osmotic diuretic)
• Positive test: ≥10 dB improvement in PTA or ≥12% improvement in speech discrimination score within 1–3 hours
• A positive result supports the diagnosis of endolymphatic hydrops and implies reversibility
• Useful as a diagnostic adjunct; not universally performed

7e. VEMP (Vestibular-Evoked Myogenic Potentials)

• Cervical VEMP (cVEMP) tests the saccule and inferior vestibular nerve
• Ocular VEMP (oVEMP) tests the utricle and superior vestibular nerve
• Abnormal in advanced MD; can help lateralize the lesion

7f. Imaging

• MRI with gadolinium — primary role is to exclude a vestibular schwannoma or endolymphatic sac tumor
• Delayed gadolinium MRI (intravenous or intratympanic gadolinium with high-Tesla MRI): can directly visualize endolymphatic hydrops, but not yet in standard diagnostic criteria
• CT temporal bone: reduced vestibular aqueduct width/pneumatization supports diagnosis

8. Treatment

8a. Acute Attack Management

• Vestibular suppressants: Meclizine, dimenhydrinate, promethazine
• Antiemetics: Prochlorperazine, ondansetron
• Benzodiazepines: Lorazepam (acute sedation and vestibular suppression)
• Rest in a quiet, dark environment
• IV hydration if vomiting is severe

8b. Medical Prophylaxis (First-Line)

• Sodium restriction: <2 g/day (reduces endolymph production by altering body fluid homeostasis)
• Diuretics: Hydrochlorothiazide/triamterene (Dyazide) most common; acetazolamide also used
• First proposed by Furstenberg; widely accepted despite limited level 1 evidence for hearing preservation

• Betahistine (histamine H₃ antagonist/weak H₁ agonist): improves cochlear microcirculation, enhances endolymph absorption; widely used in Europe (16–48 mg TID); evidence remains mixed
• Vasodilators (cinnarizine, nimodipine)
• Caffeine and alcohol restriction
• Stress reduction

8c. Intratympanic Therapies

• Dexamethasone 4 mg/mL or methylprednisolone most commonly used
• Delivered through a tympanostomy tube or by injection across the tympanic membrane
• Vertigo control achieved in ~70–80% of patients in some series
• No proven effect on hearing loss — multiple RCTs have failed to show hearing benefit
• Mechanism: anti-inflammatory + possible mineralocorticoid effects on Na⁺/K⁺ channel activity in the stria vascularis
• 2025 systematic review (PMID 40421807) confirms role of IT gentamicin for refractory cases

• Low-dose gentamicin selectively destroys vestibular hair cells (type I > type II) while relatively sparing cochlear function
• Protocols: single injection, titration (inject until vertigo is controlled or caloric hypofunction confirmed), or multiple fixed-dose injections
• Vertigo control: 80–90% in most series
• Risk of SNHL: 10–30% (dose-dependent)
• Preferred when vertigo is disabling and hearing is already significantly reduced
• 2025 meta-analysis (PMID 40421807) confirms effectiveness for vertigo control

8d. Surgical Treatment

Hearing-Preserving Procedures

Hearing-Destructive Procedures

8e. Staging and Outcome Reporting (AAO-HNS 1996)

Important note (2024 meta-analysis, PMID 38101129): The large placebo effect in Ménière disease RCTs (up to 50–70% improvement in placebo arms) makes it extremely difficult to interpret therapeutic efficacy. The unpredictable, fluctuating nature of the disease further confounds study design.

9. Differential Diagnosis

10. Prognosis

• Spontaneous remission of vertigo attacks occurs in ~60% of patients over time
• Hearing loss progresses over the years in most, though at variable rates; profound loss is rare
• Eventually, the attacks often "burn out" as vestibular function is destroyed — but the patient is left with chronic imbalance and significant hearing loss
• Bilateral disease worsens the prognosis considerably

11. Associated Conditions

• Migraine — strong bidirectional association, especially in familial cases
• Autoimmune disease — association with HLA-B8/DR3; autoimmune inner ear disease may represent a spectrum
• Thyroid disease — 2025 meta-analysis (PMID 40134376) confirms a significant association between Ménière disease and thyroid pathology
• Anxiety and depression — common comorbidities given the unpredictable disabling nature of attacks

• IT gentamicin meta-analysis 2025 (PMID 40421807) — confirms gentamicin effectiveness for refractory vertigo
• Placebo effect in Ménière RCTs (PMID 38101129) — highlights the significant placebo response confounding trial interpretation
• Ménière disease & thyroid disease association (PMID 40134376) — 2025 meta-analysis confirming association